ChevronTexaco and Former Chevron Chairman Make Major Contributions to UCSF to Fight Prostate and Breast Cancer
SAN RAMON, Calif., Jul. 13, 2004 -- ChevronTexaco announced today that it is contributing $1 million to the University of California, San Francisco (UCSF), to fight prostate and breast cancer, and that former Chevron Chairman and CEO Ken Derr and his wife Donna also are donating $1.5 million to UCSF to support prostate cancer research.
"Our hope is that these funds will act as a catalyst for positive change in the battle against prostate and breast cancer," said David J. O'Reilly, chairman and CEO of ChevronTexaco.
ChevronTexaco contributed $500,000 to the UCSF San Francisco Mammography Registry: A Research Resource (SFMR), which collects demographic, clinical and risk factor information to study and combat breast cancer. The other $500,000 from ChevronTexaco, along with the Derrs' gift, will establish the Ken and Donna Derr-ChevronTexaco Distinguished Professorship in Prostate Cancer, which will be held by Peter R. Carroll, M.D., chair of UCSF's Department of Urology. Dr. Carroll is recognized as a global leader in the field of prostate cancer research and treatment.
"Donna and I are pleased to contribute to the groundbreaking work of Dr. Carroll. This contribution reflects a shared commitment with UCSF to prevent and cure prostate cancer and improve the quality of life for men undergoing treatment," said Mr. Derr, who was treated at UCSF in 1998 for prostate cancer.
Mr. Derr retired in 1999 after a distinguished career of almost 40 years with Chevron, including 11 years as chairman and CEO. To honor his years of service to the company, ChevronTexaco contributed $500,000 to UCSF in 2000 for prostate cancer research.
UCSF is one of the world's premier health sciences universities, a leader in biomedical research, patient care, higher education and public service.
"Discovering the fundamental biological processes underlying prostate cancer and translating those discoveries into new ideas for prevention, diagnosis and treatment is our primary emphasis," said Dr. Carroll. "These generous contributions allow us to continue our search for answers and allow those affected by prostate cancer to live longer, fuller lives."
"ChevronTexaco's gift to the San Francisco Mammography Registry allows it to continue ongoing data collection in Marin and San Francisco counties and to use the data to answer clinically relevant research questions of value to women about mammography and breast cancer," said Karla Kerlikowske, M.D., principal investigator of the SFMR and associate professor of Medicine and Epidemiology and Biostatistics.
Breast cancer is the most common cancer among women, other than skin cancer, according to the American Cancer Society (ACS). This year, 215,990 women in the United States will be found to have invasive breast cancer and about 40,110 women will die from the disease. In 2004, ACS reports that 230,900 new cases of prostate cancer are expected in the United States, with approximately 29,900 men dying of the disease. ACS notes that breast and prostate cancer death rates are going down, a likely result of earlier detection and improved treatment.
In 2003, ChevronTexaco made community investments around the world of $60.8 million. Currently celebrating its 125th anniversary, ChevronTexaco is the second-largest U.S.-based energy company and the fifth largest in the world, based on market capitalization. More than 50,000 ChevronTexaco employees work in approximately 180 countries around the world, producing and transporting crude oil and natural gas, and marketing and distributing fuels and other energy products. ChevronTexaco is based in San Ramon, California.
Updated: July 2004